Form 8-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

Form 8-K

 

 

Current Report

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

February 17, 2006

Date of Report

(Date of earliest event reported)

 

 

DURECT CORPORATION

(Exact name of Registrant as specified in its charter)

 

 

Delaware   000-31615   94-3297098

(State or other jurisdiction of

incorporation or organization)

   (Commission File Number)  

(I.R.S. Employer

Identification No.)

 

10240 Bubb Road

Cupertino, CA 95014

(Address of principal executive offices) (Zip code)

 

(408) 777-1417

(Registrant’s telephone number, including area code)

 

 

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Item 8.01 Other Events.

 

On February 17, 2006, DURECT Corporation, a Delaware corporation (“DURECT”), issued a press release announcing that Remoxy™, an abuse-resistant pain medicine under development based on DURECT’s patented ORADUR™ technology incorporating the opioid oxycodone has successfully completed a Special Protocol Assessment with the U.S. Food and Drug Administration (FDA) and that a pivotal Phase III trial is being commenced on Remoxy in 400 patients with severe chronic pain.

 

Item 9.01. Financial Statements and Exhibits.

 

(c) Exhibits

 

99.1    Press Release of DURECT Corporation dated February 17, 2006

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    DURECT Corporation
Date: February 17, 2006   By:  

/s/ James E. Brown

        James E. Brown
        President and Chief Executive Officer

DURECT CORPORATION

 

INDEX TO EXHIBITS

 

Exhibit
Number
  

Description

99.1   Press Release of DURECT Corporation dated February 17, 2006